ACM Global Laboratories is proud to be involved with a fully-enrolled clinical study of an inactivated, adjuvanted COVID-19 vaccine candidate developed by Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The vaccine candidate, VLA2001, is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.
In June 2021, Valneva announced that 4,000 volunteers across the United Kingdom have been randomized in the Phase 3 trial “Cov-Compare” (VLA2001-301). This trial compares Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria. Cov-Compare’s primary endpoint is to determine the immune response (Geometric Mean Titer – GMT of SARS-CoV-2-specific neutralizing antibodies) two weeks after completion of a two-dose immunization schedule administered in a four-week interval. Data from this study is expected early in the fourth quarter of 2021. To support future approval in further age groups, Valneva has also commenced recruitment of adolescents, aged 12 to 17 years, in the United Kingdom.
ACM Global Laboratories is a recognized leader in global clinical trial testing services, supporting research studies in more than 65 countries around the globe. With a focus on quality and the ability to provide the skills and bandwidth needed to deliver robust central laboratory services, our scientific experts, project managers and other professionals offer effective strategies and solutions to efficiently execute COVID-19 clinical trials through in-house testing. Especially through our work with studies such as the Valneva vaccine trial, a trial in which we are involved throughout its entirety, we are helping to accelerate the end of the pandemic through our flexible and consultative approach.
“As experts around the world continue to develop COVID-19 vaccines and therapeutic compounds, ACM Global Laboratories stands ready to support and optimize these trials,” said ACM Global Laboratories Chief Commercial Officer, Thomas Mueller. “We are committed to using our resources to help defeat the virus and end the pandemic.”
ACM Global Laboratories, an affiliate of Rochester Regional Health, is one of the largest global independent central labs in the industry. ACM is certified by the College of American Pathologists (CAP) and the Substance Abuse and Mental Health Services Administration (SAMHSA). The company delivers high-quality laboratory testing and diagnostic lab services in support of both clinical trials research, toxicology and individual patient care. ACM provides a powerful combination of operational excellence, scientific expertise and unsurpassed global service to customers in more than 65 countries. ACM performs more than 30 million laboratory tests each year—spanning all medical disciplines including pathology, microbiology, molecular diagnostics, toxicology and more. For more information, visit ACMGlobalLab.com.
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Pharm-Olam is a global clinical research organization that delivers right-sized trial services to pharmaceutical, biotechnology, government, and public health organizations around the world. They specialize in small molecule therapies and biologics in infectious disease, and vaccines oncology-hematology, rare disease, allergy, autoimmune, infectious disease, and vaccines. Founded in 1994, with operations in 60 countries, this CRO goes the distance to create a healthier world through agile, innovative, and customized CRO solutions for Phase I-IV research. Learn how Pharm-Olam helps studies succeed at www.pharm-olam.com.